Dr. Delaune is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1580 Beam Ave
Maplewood, MN 55109Phone+1 651-779-7978Fax+1 651-779-7656
Education & Training
- University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 1994 - 1997
- Vanderbilt University Medical CenterResidency, Internal Medicine, 1991 - 1994
- McGovern Medical School at UTHealthClass of 1991
Certifications & Licensure
- MN State Medical License 1997 - 2025
- WI State Medical License 1997 - 2007
- TX State Medical License 1995 - 1998
- TN State Medical License 1994 - 1995
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Top MD Consumers Checkbook
Clinical Trials
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
- Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Start of enrollment: 2008 May 15
- Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Start of enrollment: 2008 Jun 15
- Join now to see all
Publications & Presentations
PubMed
- 39 citationsAzacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.Guru Sonpavde, Ana Aparicio, Feng Zhan, Brittany North, Robert Delaune
Urologic Oncology. 2011-11-01 - 47 citationsPlacebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid–Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome...Sherry L. Wolf, Rui Qin, Smitha Menon, Kendrith M. Rowland, Sachdev P. Thomas
Journal of Clinical Oncology. 2010-12-10 - 14 citationsA phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.Scott H. Okuno, Robert Delaune, Jeff A. Sloan, Nathan R. Foster, Matthew J. Maurer
Cancer. 2008-04-15
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: